Happy to participate to the 15th Forum for Cellular and Humoral Immunotherapy today at 4pm CET.

I will discuss the risks of secondary malignancy after #CARTcell therapy.

Feel free to register👉 us06web.zoom.us/webinar/regi...

Honored to present our latest #RomeeLab research on engineering IL-12-secreting CAR NK cells to target high-risk AML—demonstrating feasibility, safety, and efficacy.

What a pleasure to be at #EBMT25 in Florence! 🇮🇹🌞

Delighted to see a packed and engaged audience at the Quality Management Session 3 on the 9th edition of the FACT-JACIE standards!

#EBMT25

Deep gratitude to my co-authors: Vincent Guiraud, Sylvain Choquet, Catherine Thieblemont, Emmanuel Bachy, Stéphane Barete, Ève Todesco, Bertrand Arnulf, Nicolas Boissel, André Baruchel, Jacques-Olivier Bay, Steven Le Gouill, and Roch Houot. And many thanks to all the principal investigators.

Only 1 case (0.03%) of T-cell malignancy was observed:

A 73-year-old woman, treated with CAR T-cells in the third line for relapsing DLBCL, developed a primary cutaneous CD30+ T-cell lymphoproliferative disorder (ALK-) 3 years post-infusion.

Here's what we found:

Of 3,066 pediatric and adult patients, including 2,536 with B-cell lymphoma, 162 with B-cell ALL, and 368 with multiple myeloma, the cumulative incidence of secondary T-cell malignancy was:
- 0% at 1, 2, and 3 years.
- 0.6% (95% CI: 0.1–3.1) at 4 years.

Thanks @Razan_Mohty for this excellent selection of abstracts on cellular therapy for acute leukemia!

I am excited to also highlight this great study from #RomeeLab which will be presented on Monday, December 9 at #ASH24 by Ji Eun Jang.

ash.confex.com/ash/2024/web... @ash-hematology.bsky.social

A highly anticipated new CAR-T cell therapy for B-cell ALL and a great news for the patients!

Congratulations to Claire Roddie and the team behind the FELIX trial, leading to the FDA approval of Obecabtagene autoleucel.

Read the full article here: www.nejm.org/doi/full/10....